Skip to main content

Table 1 Comparison of outcomes between women who received misoprostol or placebo, expressed as proportions (percent) or mean values [standard deviation]. Differences are expressed as relative risks or mean differences, with 95% confidence intervals.

From: Misoprostol for treating postpartum haemorrhage: a randomized controlled trial [ISRCTN72263357]

  Misoprostol (117) Placebo (121)   
Baseline characteristics n   n    
Age (years) 116 27.1 [6.0] 119 26.2 [6.2]   
Ergometrine before enrolment 106 36 (34%) 104 34 (33%)   
Oxytocin ≥20 U before enrolment 116 82 (71%) 117 78 (67%)   
Primary outcomes:      RR/ MD 95% Conf. interval
Blood loss ≥500 ml* 117 6 (5.1%) 120 11 (9.2%) 0.56 0.21 to 1.46
Mean blood loss* [SD] (ml) 117 168 [163] 120 176 [173] -8 -51 to 35
24 hour Haemoglobin <6 g/dL or blood transfusion 110 20 (18.2%) 116 17 (14.7%) 1.24 0.69 to 2.24
Pyrexia at 1 hour ≥38, 5°C 114 11 (9.6%) 118 2 (1.7%) 5.69 1.29 to 25
Shivering at 1 hour ≥ moderate 116 63 (54%) 118 30 (25%) 2.14 1.50 to 3.04
Secondary outcomes:       
Blood loss ≥ 1,000 ml* 117 1 (0.85%) 120 0 (0%)   
Blood transfusion 115 19 (17%) 119 15 (13%) 1.31 0.70 to 2.45
24 hour haemoglobin <8 g/dL or blood transfusion 110 43 (39%) 116 37 (32%) 1.23 0.86 to 1.75
Additional uterotonic after enrolment 111 63 (57%) 112 63 (56%) 1.01 0.80 to 1.27
Manual removal of the placenta 117 1 (0.85%) 121 4 (3.3%) 0.26 0.03 to 2.28
Evacuation of retained products of conception 117 2 (1.7%) 121 0 (0%)   
Hysterectomy** 117 3 (2.6%) 121 0 (0%)   
Maternal death** 117 3 (2.6%) 121 0 (0%)   
  1. RR = relative risk; MD = mean difference; Conf = confidence; SD = standard deviation *Measured, within 1 hour after enrolment ** One woman died after hysterectomy and is counted in both outcomes